An Open-label Pharmacokinetic and Safety Study of Cabazitaxel in Patients With Solid Tumors With Moderately and Severely Impaired and With Normal Renal Function.

Trial Profile

An Open-label Pharmacokinetic and Safety Study of Cabazitaxel in Patients With Solid Tumors With Moderately and Severely Impaired and With Normal Renal Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Sanofi
  • Most Recent Events

    • 03 Dec 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 May 2012 Actual initiation date changed from Feb 2012 to Apr 2012, as reported by ClinicalTrials.gov.
    • 22 May 2012 Planned end date changed from 1 Jul 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top